Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tremelimumab: First Approval
Susan J. Keam
Drugs (2022) Vol. 83, Iss. 1, pp. 93-102
Open Access | Times Cited: 72

Showing 26-50 of 72 citing articles:

Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer
Ran Ni, Zhiming Hu, Ran Tao
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117430-117430
Open Access | Times Cited: 4
CD8+ T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy
Biao Zhang, Jinming Liu, Yuying Mo, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
The Efficacy and Safety of Durvalumab and Tremelimumab with Concomitant Treatment for MSS/pMMR Metastatic Colorectal Cancer: A Single Arm Meta-Analysis
Danning Zhang, Tianyu Chen
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors
Fei Du, Guojun Wang, Qian Dai, et al.
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
A research protocol for a prospective, multicenter, cohort study on interferon therapy for chronic hepatitis B combined with metabolism-associated fatty liver disease to achieve clinical cure
Daqiong Zhou, Chao Zhang, Lu Zhang, et al.
Frontiers in Public Health (2025) Vol. 13
Open Access
Recent developments on checkpoint inhibitors, CAR T cells, and beyond for T cell-based immunotherapeutic strategies against cancer
Shaukat Ali, Mahnoor Arshad, Muhammad Summer, et al.
Journal of Oncology Pharmacy Practice (2025)
Closed Access
Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies
Reshmi S. Nair, Veena Somasundaram, Anshu Kuriakose, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?
Riccardo Nevola, Augusto Delle Femine, Valerio Rosato, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2950-2950
Open Access | Times Cited: 10
Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma
Perla Chami, Youssef Diab, Danny N. Khalil, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 16773-16773
Open Access | Times Cited: 9
Pharmacological Profile of FDA-Approved Orphan Drugs in the Year 2022
Parveen Kumar Goyal, Kavita Sangwan
Current Pharmacology Reports (2024) Vol. 10, Iss. 2, pp. 96-120
Closed Access | Times Cited: 3
Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives
Valeria De Gaetano, Maria Pallozzi, Lucia Cerrito, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1388-1388
Open Access | Times Cited: 3
Dendritic nanoparticles for immune modulation: a potential next-generation nanocarrier for cancer immunotherapy
DaWon Kim, Kaila Javius-Jones, Narsimha Mamidi, et al.
Nanoscale (2024) Vol. 16, Iss. 21, pp. 10208-10220
Closed Access | Times Cited: 3
Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons
William Karlsen, Lin Akily, M. Mierzejewska, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 1990-1990
Open Access | Times Cited: 3
Emerging Strategies for Local Delivery of Immune Checkpoint Inhibitors to Potentiate Cancer Immunotherapy: Current Status and Future Prospects
Xin Chen, Wei Ding, Yuchen Jiang, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 44, pp. 59682-59696
Closed Access | Times Cited: 3
The effect of liver disease on hepatic microenvironment and implications for immune therapy
Zachary J. Brown, Samantha M. Ruff, Timothy M. Pawlik
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 9
Self-Assembled Nanobiomaterials for Combination Immunotherapy
Johns Paul, Priyanka Sharma, Asifkhan Shanavas
ACS Applied Bio Materials (2023) Vol. 7, Iss. 8, pp. 4962-4974
Closed Access | Times Cited: 8
Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A Review
Kavita Sangwan, Vipasha Sharma, Parveen Kumar Goyal
Current Molecular Medicine (2023) Vol. 24, Iss. 6, pp. 734-750
Closed Access | Times Cited: 7
An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer
Himil Mahadevia, Pedro Luiz Serrano Usón, Jing Wang, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 1, pp. 79-90
Closed Access | Times Cited: 2
A Novel Algorithm for the Virtual Screening of Extensive Small Molecule Libraries Against ERCC1/XPF Protein-Protein Interaction for the Identification of Therapeutic Resistance-Bypassing Small Anticancer Molecules
Tuğba Gül Inci, Serap Acar, Dilek Turgut‐Balik
TURKISH JOURNAL OF BIOLOGY (2024) Vol. 48, Iss. 2, pp. 112-132
Open Access | Times Cited: 2
Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives
Jianzhong Liu, Shuai Xia, Baoyi Zhang, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Microbiota and Cytokine Modulation: Innovations in Enhancing Anticancer Immunity and Personalized Cancer Therapies
Hamidreza Farhadi Rad, Hamed Tahmasebi, Samaneh Javani, et al.
Biomedicines (2024) Vol. 12, Iss. 12, pp. 2776-2776
Open Access | Times Cited: 2
Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors
Xiangxiao Hu, Lina Wang, Bin Shang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?
Anna Maria Di Giacomo, Michael Lahn, Alexander M.M. Eggermont, et al.
European Journal of Cancer (2023) Vol. 198, pp. 113501-113501
Open Access | Times Cited: 5
Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system
Yibei Zhao, Huiming Jiang, Lifen Xue, et al.
International Journal of Clinical Pharmacy (2024) Vol. 46, Iss. 2, pp. 480-487
Closed Access | Times Cited: 1
Online searches for hepatocellular carcinoma drugs mirror prescription trends across specialties and changes in guideline recommendations
Philipp Berning, Adrian E. Schroer, Rishav Adhikari, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1

Scroll to top